Table 3.
Subgroup analyses of CAP based on BMI, treatment duration, age, type of SGLT2i, and baseline of LSM and CAP.
| Criteria for grouping | Subgroups | n | WMD (95%CI) | I2 (%) | Z | p |
|---|---|---|---|---|---|---|
| BMI | >30 kg/m2 | 4 | −11.71 (−20.97, −2.45) | 51.7 | −2.478 | 0.013 |
| <30 kg/m2 | 5 | −14.75 (−27.81, −1.69) | 82.4 | −2.213 | 0.027 | |
| Treatment duration | ≥24 weeks | 6 | −12.81 (−20.40, −5.22) | 36.2 | −3.309 | 0.001 |
| <24 weeks | 3 | −13.87 (−30.76, 3.03) | 90.4 | −1.608 | 0.108 | |
| Age | >55 years | 2 | −16.60 (−37.56, 4.36) | 38.4 | −1.552 | 0.121 |
| <55 years | 7 | −12.18 (−20.83, −3.53) | 78.7 | −2.759 | 0.006 | |
| Type of SGLT2i | Dapagliflozin | 5 | −14.75 (−27.81, −1.69) | 82.4 | −2.213 | 0.027 |
| Empagliflozin | 3 | −6.38 (−15.30, 2.54) | 0 | −1.402 | 0.161 | |
| Ipragliflozin | 1 | −19.70 (−26.56, −12.84) | 0 | −5.628 | <0.001 | |
| Baseline of LSM | >7.3 kPa | 4 | −16.34 (−31.65, −1.03) | 86.8 | −2.092 | 0.036 |
| <7.3 kPa | 4 | −6.62 (−14.74, 1.50) | 0 | −1.598 | 0.110 | |
| Baseline of CAP | >292 dB/m | 6 | −16.96 (−26.47, −7.46) | 65.4 | −3.499 | <0.001 |
| <292 dB/m | 3 | −5.56 (−13.39, 2.26) | 41.7 | −1.394 | 0.163 |
BMI, body mass index; n, number of studies; SGLT2i, sodium-glucose cotransporter 2 inhibitors; LSM, liver stiffness measurement; CAP, controlled attenuation parameter.